Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:BSTC's Cash-to-Debt is ranked higher than
99% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:BSTC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BSTC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.87
NAS:BSTC's Equity-to-Asset is ranked higher than
80% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:BSTC: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BSTC' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.34  Med: 0.85 Max: 0.98
Current: 0.87
-5.34
0.98
Interest Coverage No Debt
NAS:BSTC's Interest Coverage is ranked higher than
99% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:BSTC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:BSTC' s Interest Coverage Range Over the Past 10 Years
Min: 80.45  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 27.38
Beneish M-Score: -2.13
WACC vs ROIC
15.83%
168.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 65.32
NAS:BSTC's Operating Margin % is ranked higher than
98% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:BSTC: 65.32 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BSTC' s Operating Margin % Range Over the Past 10 Years
Min: -296.7  Med: 45.75 Max: 65.32
Current: 65.32
-296.7
65.32
Net Margin % 43.43
NAS:BSTC's Net Margin % is ranked higher than
96% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAS:BSTC: 43.43 )
Ranked among companies with meaningful Net Margin % only.
NAS:BSTC' s Net Margin % Range Over the Past 10 Years
Min: -300.13  Med: 34.86 Max: 57.93
Current: 43.43
-300.13
57.93
ROE % 22.29
NAS:BSTC's ROE % is ranked higher than
94% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:BSTC: 22.29 )
Ranked among companies with meaningful ROE % only.
NAS:BSTC' s ROE % Range Over the Past 10 Years
Min: -31.9  Med: 20.47 Max: 61.21
Current: 22.29
-31.9
61.21
ROA % 19.12
NAS:BSTC's ROA % is ranked higher than
96% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NAS:BSTC: 19.12 )
Ranked among companies with meaningful ROA % only.
NAS:BSTC' s ROA % Range Over the Past 10 Years
Min: -156.91  Med: 18.9 Max: 53.14
Current: 19.12
-156.91
53.14
ROC (Joel Greenblatt) % 413.90
NAS:BSTC's ROC (Joel Greenblatt) % is ranked higher than
97% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NAS:BSTC: 413.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BSTC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -406600  Med: 161.12 Max: 413.9
Current: 413.9
-406600
413.9
3-Year Revenue Growth Rate 20.00
NAS:BSTC's 3-Year Revenue Growth Rate is ranked higher than
73% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:BSTC: 20.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BSTC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.8  Med: 6.75 Max: 65.2
Current: 20
-46.8
65.2
3-Year EBITDA Growth Rate 30.70
NAS:BSTC's 3-Year EBITDA Growth Rate is ranked higher than
82% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. NAS:BSTC: 30.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:BSTC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.7 Max: 157.7
Current: 30.7
0
157.7
3-Year EPS without NRI Growth Rate 27.10
NAS:BSTC's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:BSTC: 27.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BSTC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.3  Med: 2.35 Max: 104.1
Current: 27.1
-60.3
104.1
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BSTC's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NERV, AMEX:BTX, OTCPK:PTCHF, NAS:ASMB, NAS:MRUS, NAS:SELB, NAS:NVAX, OTCPK:NICXF, NAS:CNCE, NAS:CLDX, NAS:SVA, NAS:CRBP, NAS:AGEN, NAS:EDGE, NAS:CRIS, NAS:PETX, NAS:ARGX, NAS:OCUL, NAS:CCXI, NAS:OVID » details
Traded in other countries:1B3.Germany,
Headquarter Location:USA
BioSpecifics Technologies Corp is a biopharmaceutical company engaged in the development of an injectable collagenase for multiple indications.

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted disease are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive cabsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Ratios

vs
industry
vs
history
PE Ratio 30.69
BSTC's PE Ratio is ranked higher than
53% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.55 vs. BSTC: 30.69 )
Ranked among companies with meaningful PE Ratio only.
BSTC' s PE Ratio Range Over the Past 10 Years
Min: 15.05  Med: 34.15 Max: 88.33
Current: 30.69
15.05
88.33
Forward PE Ratio 29.15
BSTC's Forward PE Ratio is ranked lower than
68% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. BSTC: 29.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.69
BSTC's PE Ratio without NRI is ranked higher than
55% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.76 vs. BSTC: 30.69 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSTC' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.05  Med: 34.15 Max: 88.33
Current: 30.69
15.05
88.33
PB Ratio 5.99
BSTC's PB Ratio is ranked lower than
66% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BSTC: 5.99 )
Ranked among companies with meaningful PB Ratio only.
BSTC' s PB Ratio Range Over the Past 10 Years
Min: 4.64  Med: 7.58 Max: 571.43
Current: 5.99
4.64
571.43
PS Ratio 13.34
BSTC's PS Ratio is ranked lower than
52% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. BSTC: 13.34 )
Ranked among companies with meaningful PS Ratio only.
BSTC' s PS Ratio Range Over the Past 10 Years
Min: 2.54  Med: 14.65 Max: 72.53
Current: 13.34
2.54
72.53
Price-to-Free-Cash-Flow 29.66
BSTC's Price-to-Free-Cash-Flow is ranked higher than
50% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 28.96 vs. BSTC: 29.66 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSTC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.9  Med: 45.45 Max: 3552.86
Current: 29.66
13.9
3552.86
Price-to-Operating-Cash-Flow 29.66
BSTC's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 25.50 vs. BSTC: 29.66 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSTC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.9  Med: 45.45 Max: 3552.86
Current: 29.66
13.9
3552.86
EV-to-EBIT 17.37
BSTC's EV-to-EBIT is ranked higher than
61% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. BSTC: 17.37 )
Ranked among companies with meaningful EV-to-EBIT only.
BSTC' s EV-to-EBIT Range Over the Past 10 Years
Min: -128.8  Med: 17.1 Max: 63.9
Current: 17.37
-128.8
63.9
EV-to-EBITDA 15.77
BSTC's EV-to-EBITDA is ranked higher than
56% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. BSTC: 15.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSTC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.2  Med: 16.6 Max: 62.9
Current: 15.77
-132.2
62.9
PEG Ratio 1.00
BSTC's PEG Ratio is ranked higher than
70% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 2.15 vs. BSTC: 1.00 )
Ranked among companies with meaningful PEG Ratio only.
BSTC' s PEG Ratio Range Over the Past 10 Years
Min: 0.71  Med: 0.92 Max: 1.11
Current: 1
0.71
1.11
Shiller PE Ratio 89.21
BSTC's Shiller PE Ratio is ranked lower than
66% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.27 vs. BSTC: 89.21 )
Ranked among companies with meaningful Shiller PE Ratio only.
BSTC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 84.98  Med: 199.48 Max: 1349
Current: 89.21
84.98
1349
Current Ratio 21.20
BSTC's Current Ratio is ranked higher than
93% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BSTC: 21.20 )
Ranked among companies with meaningful Current Ratio only.
BSTC' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 6.63 Max: 48.18
Current: 21.2
0.43
48.18
Quick Ratio 21.20
BSTC's Quick Ratio is ranked higher than
93% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BSTC: 21.20 )
Ranked among companies with meaningful Quick Ratio only.
BSTC' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 5.9 Max: 48.18
Current: 21.2
0.41
48.18
Days Sales Outstanding 65.71
BSTC's Days Sales Outstanding is ranked lower than
51% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. BSTC: 65.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSTC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.28  Med: 115.13 Max: 299.91
Current: 65.71
26.28
299.91

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
BSTC's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. BSTC: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSTC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6  Med: -1.9 Max: 2.7
Current: -4.1
-6
2.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.11
BSTC's Price-to-Net-Cash is ranked lower than
56% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. BSTC: 9.11 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BSTC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.85  Med: 13.44 Max: 133.33
Current: 9.11
2.85
133.33
Price-to-Net-Current-Asset-Value 7.68
BSTC's Price-to-Net-Current-Asset-Value is ranked lower than
51% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. BSTC: 7.68 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BSTC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.05  Med: 7.06 Max: 40.52
Current: 7.68
1.05
40.52
Price-to-Tangible-Book 6.02
BSTC's Price-to-Tangible-Book is ranked lower than
56% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. BSTC: 6.02 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BSTC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.59  Med: 5.12 Max: 485.71
Current: 6.02
0.59
485.71
Price-to-Intrinsic-Value-Projected-FCF 2.48
BSTC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
61% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.46 vs. BSTC: 2.48 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSTC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 3.36 Max: 364.29
Current: 2.48
0.52
364.29
Price-to-Median-PS-Value 0.91
BSTC's Price-to-Median-PS-Value is ranked higher than
58% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BSTC: 0.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSTC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.55 Max: 4.12
Current: 0.91
0.04
4.12
Price-to-Peter-Lynch-Fair-Value 1.23
BSTC's Price-to-Peter-Lynch-Fair-Value is ranked higher than
69% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. BSTC: 1.23 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BSTC' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.61  Med: 1.2 Max: 2.67
Current: 1.23
0.61
2.67
Price-to-Graham-Number 2.87
BSTC's Price-to-Graham-Number is ranked lower than
51% of the 190 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. BSTC: 2.87 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BSTC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.87  Med: 2.82 Max: 9.41
Current: 2.87
0.87
9.41
Earnings Yield (Greenblatt) % 5.75
BSTC's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. BSTC: 5.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSTC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -554.2  Med: 3.3 Max: 1356.6
Current: 5.75
-554.2
1356.6
Forward Rate of Return (Yacktman) % 36.55
BSTC's Forward Rate of Return (Yacktman) % is ranked higher than
85% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. BSTC: 36.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSTC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.9  Med: 0.2 Max: 36.9
Current: 36.55
-13.9
36.9

More Statistics

Revenue (TTM) (Mil) $27.37
EPS (TTM) $ 1.63
Beta2.28
Short Percentage of Float2.06%
52-Week Range $35.59 - 58.79
Shares Outstanding (Mil)7.17

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 30 32
EPS ($) 1.72 1.93
EPS without NRI ($) 1.72 1.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BSTC

Headlines

Articles On GuruFocus.com
Vaccine Small-Cap Just Took a Big Step Forward Jun 26 2017 
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Oracle Slowly Gaining Momentum on the Cloud Front Jun 26 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 

More From Other Websites
ETFs with exposure to Biospecifics Technologies Corp. : June 19, 2017 Jun 19 2017
Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
BioSpecifics Technologies Corp. to Present at the Jefferies 2017 Healthcare Conference Jun 02 2017
Pharma Stock With Triple-Digit Growth Forming Blotchy Base May 24 2017
Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US :... May 18 2017
BioSpecifics posts 1Q profit May 10 2017
BioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results May 10 2017
Biospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : April 21, 2017 Apr 21 2017
Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US :... Apr 20 2017
BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine... Apr 18 2017
ETFs with exposure to Biospecifics Technologies Corp. : April 7, 2017 Apr 07 2017
Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US :... Apr 07 2017
BioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference Mar 29 2017
Biospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20,... Mar 20 2017
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2016 Financial Results Mar 15 2017
Biospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US :... Mar 13 2017
Biotechs Among 5 Stocks Setting Up for Major Breakouts Mar 12 2017
Biospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US :... Jan 31 2017
BioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual... Jan 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}